Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
Emiliano Roselli,1 Rawan Faramand,2 and Marco L. Davila1,2,3,4
1Department of Clinical Science, and
2Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
3Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
4Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Find articles by
Roselli, E.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Clinical Science, and
2Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
3Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
4Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Find articles by Faramand, R. in: JCI | PubMed | Google Scholar
1Department of Clinical Science, and
2Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
3Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
4Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Find articles by
Davila, M.
in:
JCI
|
PubMed
|
Google Scholar
|
Published January 19, 2021 - More info
J Clin Invest. 2021;131(2):e142030. https://doi.org/10.1172/JCI142030.
© 2021 American Society for Clinical Investigation
Chimeric antigen receptor (CAR) T cell therapy has shown considerable promise for hematologic malignancies, leading to the US Food and Drug Administration approval of two CAR T cell–based therapies for the treatment of B cell acute lymphoblastic leukemia and large B cell lymphoma. Despite success in hematologic malignancies, the treatment landscape of CAR T cell therapy for solid tumors has been limited. There are unique challenges in the development of novel CAR T cell therapies to improve both safety and efficacy. Improved understanding of the immunosuppressive tumor microenvironment and resistance mechanisms has led to encouraging approaches to mitigating these obstacles. This Review will characterize challenges with current CAR T designs for hematologic malignancies and solid tumors and emphasize preclinical and clinical strategies to overcome them with novel CAR T cell therapies.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- JCI This Month subscription
- $135
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $195.
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)